Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics.
10.1016/j.apsb.2023.02.021
- Author:
Qing PEI
1
;
Bowen JIANG
1
;
Dengyuan HAO
1
;
Zhigang XIE
1
Author Information
1. State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
- Publication Type:Review
- Keywords:
Chemotherapy;
Combinational therapy;
Heterodimeric prodrug;
Homodimeric prodrug;
Paclitaxel;
Poly-prodrug;
Self-assembly;
Theranostics
- From:
Acta Pharmaceutica Sinica B
2023;13(8):3252-3276
- CountryChina
- Language:English
-
Abstract:
Chemotherapy has occupied the critical position in cancer therapy, especially towards the post-operative, advanced, recurrent, and metastatic tumors. Paclitaxel (PTX)-based formulations have been widely used in clinical practice, while the therapeutic effect is far from satisfied due to off-target toxicity and drug resistance. The caseless multi-components make the preparation technology complicated and aggravate the concerns with the excipients-associated toxicity. The self-assembled PTX nanoparticles possess a high drug content and could incorporate various functional molecules for enhancing the therapeutic index. In this work, we summarize the self-assembly strategy for diverse nanodrugs of PTX. Then, the advancement of nanodrugs for tumor therapy, especially emphasis on mono-chemotherapy, combinational therapy, and theranostics, have been outlined. Finally, the challenges and potential improvements have been briefly spotlighted.
